Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Eden Study & EUPHAS - 2

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Feb 03, 2024 8:38pm

204 Views

Post# 35861546

RE: Eden Study & EUPHAS - 2

Good points

I see Euphas-2 as highly reliable, corroborating evidence, that the FDA will definitely take it consideration when ruling on PMX use.

I see EDEN as additional evidence that will give doctors some more leeway in the use of PMX ( for example maybe 3 filters in some cases, or to prevent or reduce the chances of longer term organ damage e.g. AKI, etc.)

MM

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement